Instituto Butantan and SINOVAC will hold 'CoronaVac® Symposium' international event about efficacy and security of CoronaVac®

2021-11-29

Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy and security of CoronaVac® and the scientific fundamentals of the effectiveness study Project S, that took place in the municipality of Serrana.

The scientific meeting will bring together Brazilian specialists from the United States, Turkey, Chile, China and Spain who will promote deep and qualified dialogues. Among the topics discussed are: the history of the vaccine that, till this moment, is the most applied in the world protecting people from Covid-19, CoronaVac®, and its immunogenicity among elderly and pediatric population; positive responses to the third dose or booster dose and the questions abouT immunization time in different countries.

This is a free online event, open to the general public.

Day 1----7th December 2021

The main subject in the first day is the CoronaVac® development as a historical mark of international immunization to combat the SAR-CoV-2 virus, from the first base researches to the last outcomes of effectiveness and security showed in S Project, Serrana, in São Paulo and in other countries. The opening session of the symposium will be held by the president of Butantan Institute, Dimas Covas and the president of Sinovac Biotech, Weidog Yin.

8 am

Speakers: Dimas Covas (Butantan Institute) and Weidong Yin (Sinovac)

OPEN SESSION

8:30 am to 11:00 am

Chairs: Sten H. Vermund (Yale University, USA), Renato Kfouri (Brazilian Society of Immunizations, Brazil)

SESSION 1. EFFICACY, EFFECTIVENESS, SAFETY OF CORONAVAC

8:30 am

Speaker: Yaling Hu (Sinovac, China)

CORONAVAC: FROM THE BASIC RESEARCH TO THE VACCINE DEVELOPMENT

9:00 am

Speaker: Serhat Unal (Hacettepe University, Turkey)

PHASE III CLINICAL TRIAL IN TURKEY

9:20 am

Speaker: Rafael Araos (Universidad del Desarrollo, Chile)

THE EFFECTIVENESS OF CORONAVAC IN CHILE

9:40 am

Speaker:Marcos Borges (University of São Paulo, Brazil)

S PROJECT

10:00 am

Speaker:Esper G. Kallas (University of São Paulo, Brazil)

PHASE III CLINICAL TRIAL IN BRAZIL

10:20 am

GENERAL DISCUSSION

11:00 am

FINAL REMARKS (CHAIRS)

Day 2----8th December 2021

The CoronaVac underpinning Science about immunogenicity and security of the booster dose of vaccination with the inactivated SARS-CoV-2 will be presented on the second day of the international online symposium. The research outcomes will show the outreach, the potency and duration of CoronaVac immunization in several countries.

8:30 am to 11:00 am

Chairs: Yiming Shao (China, CDC), Michel Nussensweig (The Rockefeller University, USA)

SESSION 2. CELLULAR AND HUMORAL RESPONSES

8:30 am

Speaker: Edson Durigon (University of São Paulo, Brazil)

NEUTRALIZING ANTIBODIES

9:00 am

Speaker: Alexis Kalergis (P. Universidad Católica de Chile, Chile)

SAFETY AND IMMUNOGENICITY OF VACCINATION AND BOOSTERS WITH AN INACTIVATED SARS-COV-2 VACCINE IN HEALTHY ADULTS IN CHILE

9:20 am

Speaker: Xiangxi Wang (Chinese Academy of Sciences, China)

A THIRD DOSE OF INACTIVATED VACCINE AUGMENTS THE POTENCY, BREADTH, AND DURATION OF ANAMNESTIC RESPONSES AGAINST SARS-COV-2

9:40 am

Speaker: Ahmet Soysal (Memorial Ataşehir Hospital, Clinic of Pediatrics, Turkey)

COMPARISON OF IMMUNOGENICITY AND REACTOGENICITY OF INACTIVATED SARS-COV-2 VACCINE IN PREVIOUSLY SARS-COV-2 INFECTED AND UNINFECTED HEALTH CARE WORKERS

10:00 am

To be confirmed

10:20 am

GENERAL DISCUSSION

11:00 am

11:00 FINAL REMARKS (CHAIRS)

Day 3----9th December 2021

The symposium closing session will highlight the immunization outcomes among different groups of population, especially the clinic trials among patients with comorbidities, elderly, children and adolescents.

8:30 am to 11:00 am

Chairs: Rafael Franco (University of Barcelona, Spain), Paulo Andrade Lotufo (University of São Paulo)

SESSION 3. SPECIAL SUBPOPULATIONS AND PATIENTS WITH COMORBIDITIES

8:30 am

Speaker: Hongjie Yu (Fudan University, China)

IMMUNOGENICITY OF CORONAVAC AMONG THE ELDERLY AND PEDIATRIC POPULATION-BASED ON PHASE II CLINICAL TRIALS (INCLUDING BOOSTER AND PERSISTENCE)

9:00 am

Speaker: Susan M. Bueno (Pontificia Universidad Católica de Chile)

SAFETY, IMMUNOGENICITY AND EFFICACY OF AN INACTIVATED SARS-COV-2 VACCINE IN THE PEDIATRIC POPULATION IN CHILE

9:20 am

Speaker: Jiayi Wang (Sinovac, China)

SAFETY ANALYSIS AMONG THE ELDERLY AND PEDIATRIC POPULATION IN CHINA

9:40 am

Speaker: Eloisa Bonfá (University of São Paulo, Brazil)

PHASE THREE PROSPECTIVE STUDY OF SAFETY AND IMMUNOGENICITY OF CORONAVAC VACCINE IN 910 AUTOIMMUNE RHEUMATIC DISEASES PATIENTS

10:00 am

Speaker: Zijie Zhang (Yunnan University, China)

SAFETY AND IMMUNOGENICITY OF CORONAVAC IN PEOPLE WITH CHRONIC DISEASES OR LOW RESPONSE TO PRIMARY IMMUNIZATION

10:20 am

GENERAL DISCUSSION

11:00 am

FINAL REMARKS (CHAIRS)

Information from https://coronavacsymposium.butantan.gov.br/

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.